PLoS ONE (Jan 2016)

NADPH Oxidase 1 Is Associated with Altered Host Survival and T Cell Phenotypes after Influenza A Virus Infection in Mice.

  • Amelia R Hofstetter,
  • Juan A De La Cruz,
  • Weiping Cao,
  • Jenish Patel,
  • Jessica A Belser,
  • James McCoy,
  • Justine S Liepkalns,
  • Samuel Amoah,
  • Guangjie Cheng,
  • Priya Ranjan,
  • Becky A Diebold,
  • Wun-Ju Shieh,
  • Sherif Zaki,
  • Jacqueline M Katz,
  • Suryaprakash Sambhara,
  • J David Lambeth,
  • Shivaprakash Gangappa

DOI
https://doi.org/10.1371/journal.pone.0149864
Journal volume & issue
Vol. 11, no. 2
p. e0149864

Abstract

Read online

The role of the reactive oxygen species-producing NADPH oxidase family of enzymes in the pathology of influenza A virus infection remains enigmatic. Previous reports implicated NADPH oxidase 2 in influenza A virus-induced inflammation. In contrast, NADPH oxidase 1 (Nox1) was reported to decrease inflammation in mice within 7 days post-influenza A virus infection. However, the effect of NADPH oxidase 1 on lethality and adaptive immunity after influenza A virus challenge has not been explored. Here we report improved survival and decreased morbidity in mice with catalytically inactive NADPH oxidase 1 (Nox1*/Y) compared with controls after challenge with A/PR/8/34 influenza A virus. While changes in lung inflammation were not obvious between Nox1*/Y and control mice, we observed alterations in the T cell response to influenza A virus by day 15 post-infection, including increased interleukin-7 receptor-expressing virus-specific CD8+ T cells in lungs and draining lymph nodes of Nox1*/Y, and increased cytokine-producing T cells in lungs and spleen. Furthermore, a greater percentage of conventional and interstitial dendritic cells from Nox1*/Y draining lymph nodes expressed the co-stimulatory ligand CD40 within 6 days post-infection. Results indicate that NADPH oxidase 1 modulates the innate and adaptive cellular immune response to influenza virus infection, while also playing a role in host survival. Results suggest that NADPH oxidase 1 inhibitors may be beneficial as adjunct therapeutics during acute influenza infection.